Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.
Biocon Ltd. remains confident of the growth trajectory for 2025-26 (Apr-Mar) in its three core businesses--generics, contract research, development, and manufacturing organisation, and biosimilars, the company's management said in a post-earnings conference call with analysts and investors. The management said growth would be seen in the upcoming quarters driven by new product launches, majorly in the US and Europe. New launches will be seen in the generics and biosimilars segment with drugs such as Semaglutide, Liraglutide, Yesintek, and some insulin biosimilars.
Share this Story:
